BMRN
Biomarin Pharmaceutical Inc
64.10$
+0.2%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
Biomarin Pharmaceutical Inc (BMRN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 3,221 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 | 5.3 | 9.7 | 12 | 14 | 12 | 19 | 26 | 84 | 122 | 296 | 325 | 376 | 441 | 501 | 548 | 749 | 890 | 1,117 | 1,314 | 1,491 | 1,704 | 1,860 | 1,846 | 2,096 | 2,419 | 2,854 | 3,221 | |
| -0.7 | -6.1 | -6.6 | 46 | 64 | 62 | 4.0 | 2.6 | 8.7 | 18 | 53 | 66 | 70 | 84 | 92 | 88 | 122 | 152 | 210 | 242 | 315 | 359 | 524 | 471 | 503 | 532 | 580 | 737 | |
| 1.9 | 13 | 19 | 12 | 14 | 12 | 15 | 23 | 75 | 103 | 244 | 259 | 306 | 357 | 409 | 460 | 627 | 738 | 907 | 1,072 | 1,176 | 1,345 | 1,336 | 1,376 | 1,593 | 1,887 | 2,274 | 2,484 | |
| 11 | 27 | 36 | 45 | 54 | 55 | 50 | 56 | 67 | 79 | 93 | 115 | 147 | 214 | 302 | 355 | 462 | 635 | 662 | 611 | 696 | 715 | 628 | 629 | 650 | 747 | 747 | 922 | |
| 3.5 | 6.8 | 8.8 | 6.7 | 18 | 14 | 38 | 42 | 49 | 78 | 107 | 124 | 152 | 175 | 198 | 235 | 302 | 402 | 477 | 554 | 280 | 299 | 334 | 354 | 373 | 404 | 532 | 1,153 | |
| 15 | 37 | 52 | 71 | 93 | 88 | 194 | 87 | 100 | 161 | 204 | 242 | 305 | 391 | 519 | 616 | 720 | 849 | 1,711 | 1,087 | 1,300 | 1,445 | 1,380 | 1,458 | 1,432 | 1,701 | 1,789 | 1,951 | |
| -13 | -26 | -36 | -59 | -79 | -76 | -179 | -64 | -25 | -57 | 40 | 16 | 0.5 | -34 | -110 | -156 | -93 | -111 | -803 | -15 | -124 | -100 | -43 | -82 | 161 | 186 | 484 | 533 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 3.1 | 11 | 12 | 17 | 14 | 16 | 14 | 10 | 8.3 | 7.6 | 10 | 37 | 38 | 39 | 43 | 44 | 23 | 29 | 15 | 16 | 17 | 13 | 11 | |
| -12 | -29 | -40 | -71 | -77 | -76 | -187 | -74 | -29 | -15 | 33 | 0.6 | -21 | -44 | -118 | -177 | -125 | -155 | -831 | -36 | -143 | -95 | -49 | -75 | 150 | 189 | 542 | 482 | |
| -0.6 | 0.6 | 4.4 | 20 | 9.8 | 0.0 | 37 | 22 | 23 | 0.7 | 2.6 | 1.1 | -227 | 10 | -3.9 | -0.2 | 9.1 | 17 | -201 | 81 | -65 | -71 | -903 | -11 | 8.0 | 21 | 115 | 134 | |
| -12 | -28 | -37 | -68 | -77 | -76 | -187 | -74 | -29 | -16 | 31 | -0.5 | 206 | -54 | -114 | -176 | -134 | -172 | -630 | -117 | -77 | -24 | 854 | -64 | 142 | 168 | 427 | 349 | |
| -12 | -20 | -30 | -41 | -59 | -66 | -135 | -54 | -15 | -53 | 67 | 36 | 17 | -0.2 | -67 | -131 | -46 | -73 | -698 | 91 | -3.4 | 32 | 84 | 47 | 265 | 307 | 651 | 573 |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.